Perspectives on Enquiry & Evidence
Cytel's blog featuring the latest industry insights.
December 6, 2023
Chemistry, Manufacturing, and Controls (CMC) is a critical component of drug product development. As a Senior...
Read article
August 23, 2018
Career Perspectives: Interview with Meredith Alm, Manager, QA Compliance
Cytel has grown significantly over the last 30 years, with operations across North America, Europe, and India. All of...
Read article
November 11, 2016
How to ensure independence of QC in statistical programming
A solid and robust QC process is one vital component of ensuring quality programming delivery. Angelo Tinazzi and...
Read article
May 15, 2015
Can You Reproduce Your Clinical Trial Results?
Imagine that it’s been three years since the completion of a trial, and that suddenly a regulatory body calls into...
Read article
September 2, 2014
Impact of Study Design and Development Strategy on Pharmaceutical Programs and Portfolios
As more clinical trials make use of adaptive designs, investors have come to realize that high quality trial designs...
Read article
August 26, 2014
Statisticians from Cytel, SAS and Stata talk Software Development
During an invited speakers session at the lnternational Society for Clinical Biostatistics, Cytel VP Yannis Jemiai was...
Read article
August 12, 2014
What Horsepower Can Teach us about Well-Powered Trials
Beyond Wild Horses: Developing Innovation at Cytel "Horse-and-pony" by arjecahn on flickr. -...
Read article
July 1, 2014
'Multivariate Approaches for Risk-Based Monitoring' An Adaptive Design (Slides Attached)
A recent Cytel Seminar on Adaptive Statistical Designs featured a talk by Michael Elashoff (Patient Profiles) on...
Read article
May 22, 2014
Data Management & Biostatistics I: Improving Trial Quality
This is the first of a three part post in which we will consider (i) improvements to trial quality that result from...
Read article